# FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

> **NCT06244004** · PHASE2 · RECRUITING · sponsor: **Northwestern University** · enrollment: 125 (estimated)

## Conditions studied

- Castration-Sensitive Prostate Carcinoma
- Metastatic Prostate Carcinoma
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Antiandrogen Therapy
- **PROCEDURE:** Bone Scan
- **PROCEDURE:** Computed Tomography
- **DRUG:** Cytotoxic Chemotherapy
- **PROCEDURE:** FDG-Positron Emission Tomography
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT06244004
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-18
- **Primary completion:** 2027-02-18
- **Final completion:** 2028-02-18
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2026-03-30

## Collaborators

- National Cancer Institute (NCI)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06244004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06244004, "FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06244004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*